Finasteride and MPHL
Medications
References
R. M. Trüeb, “Male Alopecia. Guide to Successful Management,” Springer International Publishing, 2014.
Olsen, E. A., “Androgenetic alopecia,” Disorders of Hair Growth: Diagnosis and Treatment, pp. 257–283, 2003.
Kaufman, K. D. et al., “Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group,” J Am Acad Dermatol, vol. 39, no. 4 Pt 1, pp. 578–589, Oct. 1998.
Mella, J. M. et al., “Efficacy and safety of finasteride therapy for androgenetic alopecia: A systematic review,” Arch Dermatol, vol. 146, no. 10, pp. 1141–1150, Oct. 2010.
Irwig, M. S., “Persistent sexual side effects of finasteride: could they be permanent?” J Sex Med, vol. 9, no. 11, pp. 2927–2932, Nov. 2012.
Traish, A. M. et al., “Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients,” J Sex Med, vol. 8, no. 3, pp. 872–884, Mar. 2011.
S. M. Belknap et al., “Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis,” JAMA Dermatol, vol. 151, no. 6, pp. 600–606, Jun. 2015.
Wessells, H. et al., “Effect of an alpha-blocking agent (phenoxybenzamine) in the management of prostatic obstruction,” Urology, vol. 34, no. 1, pp. 24–28, Jul. 1989.
U. S. Food and Drug Administration, “Propecia (finasteride) 1 mg tablet - FDA,” 2011. [Online]. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020788s018lbl.pdf.
Gubelin Harcha W, Barboza Martínez J, Tsai TF, Katsuoka K, Kawashima M, Tsuboi R, Barnes A, Ferron-Brady G, Chetty D. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014 Mar;70(3):489-498.e3. doi: 10.1016/j.jaad.2013.10.049. Epub 2014 Jan 9. PMID: 24411083.
Last updated
Was this helpful?